- Barrons.com•23 hours ago
Wells Fargo's and his team reiterated an Underperform rating and $10 to $13 valuation range on Valeant Pharmaceuticals (VRX) Thursday, following talks with the firm about recents staffing moves. First they asked Valeant to address rumors in the industry that some 50 of its gastrointestinal (GI) salespeople recently left Valeant en masse to join Synergy Pharmaceuticals (SGYP) following the FDA’s approval of Synergy’s plecanatide in January. Maris writes: We reached out to Synergy Pharmaceuticals which would only comment that it has been very successful in hiring a large number of experienced salespeople, many with 10+ years in GI sales.
- Business Wire•16 days ago
Synergy Pharmaceuticals Inc. today announced that Marino Garcia, the company’s EVP and Chief Strategy Officer, will participate in a fireside chat at Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 11:00 a.m.
- Business Wire•17 days agoPivotal Phase 3 Data Results for TRULANCE™ (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology
Synergy Pharmaceuticals Inc. today announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated the efficacy and safety of TRULANCE™ for the treatment of adults with chronic idiopathic constipation .
SGYP : Summary for Synergy Pharmaceuticals, Inc. - Yahoo Finance
Synergy Pharmaceuticals Inc. (SGYP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||5.41 x 4900|
|Ask||5.42 x 19600|
|Day's Range||5.34 - 5.47|
|52 Week Range||2.50 - 7.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.63|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|